Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
Bio Pharma Dive
AUGUST 24, 2022
Researchers reported signs of nerve damage in patients treated with the drug branaplam, which is among the most advanced candidates now in testing.
Let's personalize your content